Asset
ORIC-101
Oric Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03835637 | phase1 | completed | 2018-03-23 | 2018-07-04 | ORIC Pharmaceuticals | Single and Multiple Dose Study of ORIC-101 in Adult Healthy Subjects |
| NCT03928314 | phase1 | terminated | 2019-05-02 | 2022-09-22 | ORIC Pharmaceuticals | Study of ORIC-101 in Combination With Anticancer Therapy |
| NCT04033328 | phase1 | terminated | 2019-10-28 | 2022-11-22 | ORIC Pharmaceuticals | Study of ORIC-101 in Combination With Enzalutamide |
| NCT03324555 | phase1 | completed | 2017-10-19 | 2017-12-18 | ORIC Pharmaceuticals | Study of ORIC-101 in Healthy Adult Subjects |
FDA applications (0)
This company has no applications containing this asset.